Proxy Materials for RegeneRx Annual Meeting - September 10, 2014

Link to document.

Shareholder letter - Thursday May 22, 2014

Link to document.

RegeneRx Pipeline

RegeneRx Biopharmaceuticals, Inc. is a clinical-stage drug development company focused on tissue protection, repair and regeneration with an extensive portfolio of product candidates for first-in-class therapeutic peptides.

Latest News:

November 25, 2014
Researchers Report Thymosin Beta 4 is Cardioprotective in Pulmonary Hypertension/Heart Failure Model

November 6, 2014
RegeneRx Announces Management Changes

November 3, 2014
U.S. Patent Office Significantly Extends the Term of Three RegeneRx Patents

October 24, 2014
Researchers Report Thymosin Beta 4 Crosses Blood-Brain Barrier In Animal Stroke Model

October 23, 2014
Dr. Michael Chopp Reports on Successful Remodeling of the Central and Peripheral Nervous Systems after Injury/Disease Using Thymosin Beta 4

October 20, 2014
RegeneRx Allowed to Proceed with Phase 3 Using RGN-259 Eye Drops for the Treatment of Neurotrophic Keratopathy

September 30, 2014
RegeneRx Receives Canadian Patent for Inhibition or Reversal of Skin Aging